Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of Intravenous ANX005 in Amyotrophic Lateral Sclerosis
2021-000325-26Phase 2Terminated
- Sponsor
- Annexon Biosciences
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tanruprubart in amyotrophic lateral sclerosis (ALS), sponsored by Annexon Biosciences. Primary endpoints: Safety and tolerability of ANX005 up to 12 weeks, Pharmacokinetic profile of ANX005 and 1 more. Started Feb 2021; status: terminated.
02
Drugs
tanruprubart
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-000325-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000325-26.